DocKB
2 months ago
From Zack's :
CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study
08/28/2024
By John Vandermosten, CFA
NYSE:CVM
READ THE FULL CVM RESEARCH REPORT
CEL-SCI Corporation (NYSE:CVM) reported its fiscal third quarter on August 15, 2024 with the submission of its Form 10-Q with the SEC and a press release on the following day. Since our previous update for the fiscal second quarter, CEL-SCI has added several new individuals to its ranks, conducted a population analysis and presented data at IDDST for IT-MATTERS and raised additional capital to support the advance of Multikine towards the confirmatory registrational trial.
Financial Review
CEL-SCI recognized no revenues for its fiscal third quarter ending June 30, 2023 and incurred operating expenses totaling $6.7 million during the three-month period. This resulted in a net loss available to common shareholders of ($7.5) million, or ($0.14) per share.
For the quarter ending June 30, 2023 versus the same prior year period:
- Expenses for research and development fell 18% to $4.7 million from $5.7 million. Lower Phase III study, employee stock compensation and miscellaneous costs contributed to the decrease and were partially offset by increased spending to prepare for the confirmatory registration study;
- General and administrative expenses decreased 20% to $2.0 million from $2.5 million on lower consulting fees and employee stock compensation partially offset by other miscellaneous expenses;
- Other non-operating items were $14,000 compared to ($8,000) in the prior year;
- Net interest expense of ($0.2) million compared with ($0.2) million was related to lease liabilities and was relatively constant;
- Modification of warrants totaled ($659,000) compared to zero as several series of warrants received an extension of expiration dates;
- Net loss totaled ($7.5) million versus ($8.4) million or ($0.14) and ($0.19) per share, respectively.
As of June 30, 2024, cash and equivalents totaled $0.4 million. Cash burn for the three-month period amounted to approximately ($4.6) million, up from 3Q:23’s ($5.9) million. Following the end of the quarter, CEL-SCI closed on a gross $10.8 million common stock offering. CEL-SCI holds no debt on its balance sheet.
CEL-SCI Milestones
- Appointment of Mario Gobbo to Board of Directors – April 2024
- Dr. Giovanni Selvaggi joins CEL-SCI as clinical advisor – June 2024
- Presentation at the International Drug Discovery Science & Technology (IDDST) Congress – June 2024
- Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression - IT-MATTERS – RCT
- Presented by Dr. Eyal Talor
- CEL-SCI appoints Robert Watson as Chairperson of the Board – July 2024
- Feedback from various regulatory agencies - 2024
- Submission of license application to various agencies – 2024+
- Preparation for Multikine confirmatory trial - 2024
Post-Reporting Period Capital Raise
CEL-SCI announced the closing of its $10.8 million offering on July 29th in a press release. The company sold 10,845,000 shares of stock and pre-funded warrants at $1.00 per share. ThinkEquity served as the placement agent for the transaction. A post transaction summary identified 3,715,000 shares of common stock and 7,130,000 pre-funded warrants were issued.
Population Analysis
In further review of the IT-MATTERS data, CEL-SCI has conducted a bias analysis that was detailed in a July 26th press release. The analysis was conducted to ensure data quality, improve study validity, inform the interpretation of the data and to guide the upcoming confirmatory registration study. The data on patients’ age, sex, race, tumor location and staging find that the active arm and control arm are similar. It finds that the results in the study are reliable, generate reasonable conclusions and minimize the risk of bias.
The bias analysis was conducted for the Phase III study population of 923 patients with newly diagnosed resectable, locally advanced primary head and neck cancer, as well as the subgroup of 114 patients who had no lymph node involvement and had low PD-L1 tumor expression (determined via biopsy). This is the same population which will be drawn from for CEL-SCI’s upcoming confirmatory registration study.
Summary
Since our previous update, CEL-SCI has reported its latest quarterly financial and operational results, conducted a population analysis on the IT-MATTERS subjects, presented data at IDDST and added new faces to its ranks. CEL-SCI continues the planning for its anticipated confirmatory registrational study and raised an additional $10.8 million in July to further this effort. We maintain our valuation of $7.00.
DocKB
2 months ago
And some get fast-tracked:
BioAtlas Ozuriftamab Vedotin Receives FDA Fast-Track Designation; Shares Rise
9:38 AM ET 7/23/24 | MT Newswires
BioAtla's Ozuriftamab Vedotin Receives FDA Fast-Track Designation; Shares Rise
09:38 AM EDT, 07/23/2024 (MT Newswires) -- BioAtla (BCAB) said Tuesday that the US Food and Drug Administration has granted fast-track designation to ozuriftamab vedotin, the company's drug candidate to treat patients with squamous cell carcinoma of the head and neck.
The designation applies to drugs that are intended to treat a serious or life-threatening disease or condition, and have demonstrated the potential to address an unmet medical need.
"The FDA's decision is an important recognition of the potential of our CAB-ROR2-ADC, ozuriftamab vedotin," Chief Executive Jay Short said in a statement. "We look forward to discussing with the FDA plans for a potential registrational trial in the second half of this year."
rdneum
3 months ago
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This summary does not contain all the information that you should consider before investing in our securities. You should read the entire prospectus supplement and the accompanying prospectus carefully, including “Risk Factors” contained in this prospectus supplement and the accompanying prospectus, the financial statements incorporated by reference in this prospectus supplement and the accompanying prospectus, and the other documents identified under the headings “Where You Can Find Additional Information” and “Incorporation of Certain Information by Reference” in this prospectus supplement, before making an investment decision.
THE OFFERING
Common Stock we are offering
3,715,000 shares of common stock
Pre-Funded Warrants
We are also offering 7,130,000 Pre-Funded Warrants to purchase up to 7,130,000 shares of our common stock, exercisable at an exercise price of $0.01 per share, to those purchasers whose purchase of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering. The purchase price of each Pre-Funded Warrant is equal to the price per share of common stock being sold in this offering minus $0.01. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. See “Description of Pre-Funded Warrants.” This prospectus supplement also relates to the offering of the shares of common stock issuable upon the exercise of such Pre-Funded Warrants.
Common stock outstanding prior to this offering
54,268,229 shares of common stock.
Common stock to be outstanding after this offering
57,983,229 shares of common stock, assuming no exercise of any Pre-Funded Warrants.
NYSE American Symbol and Listing
Our common stock is listed on the NYSE American under the symbol “CVM.” There is no established public trading market for the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to list the Pre-Funded Warrants on the NYSE American or any other national securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited. See “Description of Pre-Funded Warrants.”
Use of Proceeds
We estimate that our net proceeds from this offering will be approximately $9,937,000, after deducting the placement agent fees and estimated offering expenses payable by us, and assuming full exercise of the Pre-Funded Warrants. We intend to use the net proceeds from this offering to fund the continued development of Multikine and for general corporate purposes and working capital. See “Use of Proceeds.”
Risk Factors
Investing in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading “Risk Factors” beginning on page S-13 of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.
The number of shares of common stock shown above to be outstanding after this offering is based on 54,268,229 shares outstanding as of July 26, 2024 and excludes:
16,322,110 shares of our common stock issuable upon the exercise of outstanding stock options at a weighted average exercise price of $6.92 per share; and
1,092,470 shares of our common stock issuable upon the exercise of warrants outstanding at a weighted average exercise price of $3.16 per share.
Except as otherwise indicated, all information in this prospectus supplement assumes (i) no exercise of the outstanding options or warrants described above; and (ii) no exercise of any Pre-Funded Warrants in this offering.